Weiden PJ - Search Results

1

Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia.

Lauriello J, Weiden PJ, Gleeson CD, Shah A, Boulanger L, Jariwala-Parikh K, Hedgeman E, O'Sullivan AK. Lauriello J, et al. Among authors: weiden pj. CNS Drugs. 2021 Oct;35(10):1123-1135. doi: 10.1007/s40263-021-00849-2. Epub 2021 Sep 21. CNS Drugs. 2021. PMID: 34546558 Free PMC article.

2

Beyond 52-Week Long-Term Safety: Long-Term Outcomes of Aripiprazole Lauroxil for Patients With Schizophrenia Continuing in an Extension Study.

Lauriello J, Claxton A, Du Y, Weiden PJ. Lauriello J, et al. Among authors: weiden pj. J Clin Psychiatry. 2020 Aug 18;81(5):19m12835. doi: 10.4088/JCP.19m12835. J Clin Psychiatry. 2020. PMID: 32841554 Free article. Clinical Trial.

3

Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia.

McEvoy JP, Weiden PJ, Lysaker PH, Sun X, O'Sullivan AK. McEvoy JP, et al. Among authors: weiden pj. BMC Psychiatry. 2021 Mar 24;21(1):164. doi: 10.1186/s12888-021-03124-2. BMC Psychiatry. 2021. PMID: 33761928 Free PMC article.

4

Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.

Weiden PJ, Du Y, von Moltke L, Wehr A, Hard M, Marandi M, Walling DP. Weiden PJ, et al. CNS Drugs. 2020 Sep;34(9):961-972. doi: 10.1007/s40263-020-00745-1. CNS Drugs. 2020. PMID: 32621071 Free PMC article. Clinical Trial.

5

Systematic Review of Real-World Treatment Patterns of Oral Antipsychotics and Associated Economic Burden in Patients with Schizophrenia in the United States.

Martin A, Bessonova L, Hughes R, Doane MJ, O'Sullivan AK, Snook K, Cichewicz A, Weiden PJ, Harvey PD. Martin A, et al. Among authors: weiden pj. Adv Ther. 2022 Sep;39(9):3933-3956. doi: 10.1007/s12325-022-02232-z. Epub 2022 Jul 18. Adv Ther. 2022. PMID: 35844007 Free PMC article.

6

Impaired insight in schizophrenia: impact on patient-reported and physician-reported outcome measures in a randomized controlled trial.

Lysaker PH, Weiden PJ, Sun X, O'Sullivan AK, McEvoy JP. Lysaker PH, et al. Among authors: weiden pj. BMC Psychiatry. 2022 Aug 28;22(1):574. doi: 10.1186/s12888-022-04190-w. BMC Psychiatry. 2022. PMID: 36031632 Free PMC article. Clinical Trial.

7

Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model.

Hard ML, Mills RJ, Sadler BM, Wehr AY, Weiden PJ, von Moltke L. Hard ML, et al. Among authors: weiden pj. CNS Drugs. 2017 Jul;31(7):617-624. doi: 10.1007/s40263-017-0447-7. CNS Drugs. 2017. PMID: 28597226 Free PMC article. Clinical Trial.

8

Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period.

Weiden PJ, Du Y, Liu CC, Stanford AD. Weiden PJ, et al. CNS Spectr. 2019 Aug;24(4):419-425. doi: 10.1017/S1092852918000986. Epub 2018 Jun 26. CNS Spectr. 2019. PMID: 29941057 Clinical Trial.

9

Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia.

Nasrallah HA, Aquila R, Du Y, Stanford AD, Claxton A, Weiden PJ. Nasrallah HA, et al. Among authors: weiden pj. CNS Spectr. 2019 Aug;24(4):395-403. doi: 10.1017/S1092852918001104. Epub 2018 Aug 15. CNS Spectr. 2019. PMID: 30109845 Clinical Trial.

10

[No title available]

[No authors listed] [No authors listed] PMID: 34127096

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

163 results

Search Page

Filters